Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OFATUMUMAB Cause Wrong technique in product usage process? 153 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 153 reports of Wrong technique in product usage process have been filed in association with OFATUMUMAB (ARZERRA). This represents 0.5% of all adverse event reports for OFATUMUMAB.

153
Reports of Wrong technique in product usage process with OFATUMUMAB
0.5%
of all OFATUMUMAB reports
0
Deaths
4
Hospitalizations

How Dangerous Is Wrong technique in product usage process From OFATUMUMAB?

Of the 153 reports, 4 (2.6%) required hospitalization, and 1 (0.7%) were considered life-threatening.

Is Wrong technique in product usage process Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OFATUMUMAB. However, 153 reports have been filed with the FAERS database.

What Other Side Effects Does OFATUMUMAB Cause?

Fatigue (5,202) Headache (4,430) Pain (3,382) Chills (3,372) Pyrexia (3,370) Influenza like illness (2,727) Nausea (1,688) Multiple sclerosis relapse (1,525) Covid-19 (1,435) Asthenia (1,393)

What Other Drugs Cause Wrong technique in product usage process?

EVOLOCUMAB (21,664) ALBUTEROL (17,114) ADALIMUMAB (11,766) PEGFILGRASTIM (10,217) ETANERCEPT (9,835) ERENUMAB-AOOE (9,359) SACUBITRIL\VALSARTAN (8,022) LEUPROLIDE (5,062) FENTANYL (2,812) SEMAGLUTIDE (2,538)

Which OFATUMUMAB Alternatives Have Lower Wrong technique in product usage process Risk?

OFATUMUMAB vs OFLOXACIN OFATUMUMAB vs OLANZAPINE OFATUMUMAB vs OLANZAPINE\SAMIDORPHAN L-MALATE OFATUMUMAB vs OLAPARIB OFATUMUMAB vs OLARATUMAB

Related Pages

OFATUMUMAB Full Profile All Wrong technique in product usage process Reports All Drugs Causing Wrong technique in product usage process OFATUMUMAB Demographics